首页 | 本学科首页   官方微博 | 高级检索  
检索        

CD133两种亚型分子在儿童B系急性淋巴细胞白血病中的表达及其临床意义
引用本文:赵文理,聂述山,许云云,张艳兰,郭豆豆,潘健,汪家敏,张学光.CD133两种亚型分子在儿童B系急性淋巴细胞白血病中的表达及其临床意义[J].中国实验血液学杂志,2012,20(3):536-540.
作者姓名:赵文理  聂述山  许云云  张艳兰  郭豆豆  潘健  汪家敏  张学光
作者单位:1. 苏州大学附属儿童医院血液科,江苏苏州,215003
2. 苏州大学附属儿童医院儿科研究所,江苏苏州,215003
3. 苏州大学医学生物技术研究所,江苏苏州,215002
基金项目:江苏省高校自然科学研究项目,苏州市科技计划项目
摘    要:本研究旨在探讨B系急性淋巴细胞白血病(B-ALL)患儿初诊和治疗33 d时CD133两种亚型分子CD133-1和CD133-2的表达及其与临床预后指标的关系。用流式细胞术检测B-ALL患儿上述两个时间点骨髓单个核细胞的CD133-1、CD133-2表达和治疗33 d时微量残留病(MRD)的变化。结果表明,B-ALL初诊组48例中CD133-1阳性表达18例(37.5%),CD133-2阳性表达30例(62.5%,P<0.05);治疗33 d组25例中CD133-1阳性表达2例(8.0%),CD133-2阳性表达23例(92.0%,P<0.05)。诱导化疗后CD133-1的表达显著减少,但高于正常对照组;而CD133-2的表达下降缓慢。结论:初诊B-ALL患者CD133表达与其性别、年龄、外周血白细胞计数、骨髓幼稚细胞比例、FAB亚型、细胞遗传学异常、融合基因表达、危险等级及完全缓解率等均无相关性。B-ALL患儿CD133-2阳性表达高于CD133-1,CD133表达与CD34表达无相关性。CD133-2的表达与MRD显著相关。

关 键 词:儿童急性淋巴细胞白血病  CD133亚型分子  微量残留病

Expression of two subtype molecules of CD133 in childhood with B linage acute lymphoblastic leukemia and its clinical significance
ZHAO Wen-Li , NIE Shu-Shan , XU Yun-Yun , ZHANG Yan-Lan , GUO Dou-Dou , PAN Jian , WANG Jia-Min , ZHANG Xue-Guang.Expression of two subtype molecules of CD133 in childhood with B linage acute lymphoblastic leukemia and its clinical significance[J].Journal of Experimental Hematology,2012,20(3):536-540.
Authors:ZHAO Wen-Li  NIE Shu-Shan  XU Yun-Yun  ZHANG Yan-Lan  GUO Dou-Dou  PAN Jian  WANG Jia-Min  ZHANG Xue-Guang
Institution:Department of Hematology, Children's Hospital of Soochow University, Suzhou, Jiangsu Province, China. zhaowenli69@yahoo.com.cn
Abstract:This study was to explore the expression of two subtype molecules of CD133 and its relationship with clinical prognostic factors in childhood with B linage acute lymphoblastic leukemia (B-ALL) at initial diagnosis and the 33rd day of induction chemotherapy. Expression of CD133-1 and CD133-2 in 48 cases of B-ALL and 25 cases at initial diagnosis and the 33rd day of treatment was detected by flow cytometry. Minimal residual disease (MRD) of B-ALL at 33rd day was evaluated by flow cytometry. The results indicated that the expression of CD133-1 was positive in 18 cases (37.5%), and expression of CD133-2 in 30 cases (62.5%) was positive from 48 cases with newly diagnosed ALL (P < 0.05). At 33rd day of treatment, expression of CD133-1 in 2 cases (8.0%) from 25 cases was positive, and expression of CD133-2 in 23 cases (92.0%) was positive (P < 0.05). After induction chemotherapy in B-ALL, the expression of CD133-1 decreased significantly, but still higher than that in the normal control group. Compared to expression of CD133-1, expression of CD133-2 decreased slowly. It is concluded that there is no relations among expression of CD133 and sex, age, white blood cell count, percentage of bone marrow blast cells, FAB subtype, cytogenetics, leukemia fusion gene, risk stratification and complete remission rate in childhood B-ALL. The positive expression rates and levels of CD133-2 are higher than those of CD133-1 in B-ALL. There is no statistical correlation between expression of CD133 and CD34 in B-ALL. The expression of CD133-2 is significantly related to the level of MRD.
Keywords:childhood acute lymphoblastic leukemia  CD133 subtype molecule  minimal residual disease
本文献已被 CNKI 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号